SAN DIEGO, May 04, 2021 - BioArdis, an oncology focused therapeutics company with programs across its cell therapy and small molecule platforms, announces Kedar Muley as Chief Business Officer and acting Chief Executive Officer. Kedar will lead the company towards advancing its therapies into clinical trials.

BioArdis, founded by Bridgewest Group, has a promising portfolio of therapeutics including drug products targeting critical functions for tumor survival and persistence and cell therapies that empower patient immune systems to target solid tumors. Dr. Masood Tayebi, Founding Partner and CEO of Bridgewest Group says "We are delighted to welcome Kedar to BioArdis. Kedar shares our passion to deliver critical, lifesaving therapies to patients in need. His extensive business leadership and successful track record for developing new business partnerships will be instrumental to advancing our portfolio of therapies towards delivering safe and impactful solutions to patients."

Kedar is a seasoned executive with nearly twenty years of biopharma, investment banking and strategic advisory experience. He spent eleven years with J.P. Morgan where he advised companies on corporate strategy, portfolio assessment and partnering, financing alternatives and mergers and acquisitions. Kedar executed nearly twenty biopharma transactions totaling over $200 billion in value throughout his tenure. Most recently, Kedar independently advised biotechnology companies on corporate development, strategy and financial planning. Kedar holds an MBA from The Wharton School of the University of Pennsylvania and a B.A. in Physics from The University of Chicago.

"I am thrilled to join BioArdis to lead its transition into a clinical-stage company, bringing its novel oncology therapies closer to treating patients," said Kedar. "BioArdis has been very proficient in developing a deep pipeline of best-in-class small molecule therapies and a cell therapy discovery engine that has generated multiple chimeric antigen receptor T-cell ("CAR-T") therapies that are optimized to target solid tumors. I am honored and excited to help take the portfolio of therapies into the next stage of development, and to facilitate BioArdis’ further development of its next-generation CAR-Ts."

BioArdis is a San Diego-based innovative therapeutics development company with a pipeline of oncology and immune-oncology drug candidates, and a novel cell therapy platform that has developed multiple chimeric antigen receptor T-cell ("CAR-T") therapies targeting solid tumors.

Founded in 1999, The Bridgewest Group is a closely held investment company that seeks to create long term value through application of superior industry knowledge, operational expertise and significant financial resources to attractive investment opportunities. The Group structures its global investments across four functional areas including private equity, real estate, capital markets and financial services. The Group's private equity investments are primarily in biotech, wireless communications, software, infrastructure for IoT, semiconductor and artificial intelligence. Bridgewest Group is based in San Diego, CA and has investments across the USA, Europe, Asia and Australasia.

SOURCE: BioArdis, LLC